



Synta to Present at the 17th Annual BIO CEO & Investor Conference

February 3, 2015

LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 3, 2015-- Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the Company will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 3:00 p.m. (ET) in New York.

A live [webcast](#) and replay of the presentation will be available on the "Investors" section of the Company's website, www.syntapharma.com.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that change cancer patients' lives. Synta's lead oncology drug candidate, ganetespib, a novel heat shock protein 90 (Hsp90) inhibitor, is currently being evaluated in several clinical trials including the pivotal GALAXY-2 Phase 3 trial in non-small cell lung cancer. Building on its extensive expertise in the science of Hsp90, Synta also has a novel proprietary Hsp90-Drug Conjugate (HDC) small molecule drug development program. IND enabling studies have commenced for the first clinical candidate from the HDC program, STA-12-8666, and preclinical evaluation of additional HDC candidates is ongoing. For more information, please visit www.syntapharma.com.

Source: Synta Pharmaceuticals Corp.

Investors:

Synta Pharmaceuticals Corp.

Daniel Cole, 781-541-7250

dcole@syntapharma.com

or

Argot Partners

Andrea Rabney, 212-600-1494

andrea@argotpartners.com

or

Media:

Argot Partners

Eliza Schleifstein, 917-763-8106

eliza@argotpartners.com